Save up -80% on Empagliflozin
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Jardiance
|$475.43||30 tablets/25 mg|
|price without discount in nearest pharmacy. Price may vary.|
We offer free Empagliflozin coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your discount card in most local pharmacies to get a discount on Empagliflozin every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Empagliflozin volume of distribution
Approximately 41.2% of the radio-labeled dose of oral empagliflozin was recovered in the feces, most of which was identified as unchanged drug. The total body clearance of empagliflozin is 10.6 L per hour and the expected half-life of empagliflozin is around 12.4 hours.
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Empagliflozin
Empagliflozin is a sodium glucose co-transporter-2 (SGLT-2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes. SGLT2 co-transporters are responsible for reabsorption of glucose from the glomerular filtrate in the kidney. The glucuretic effect resulting from SGLT2 inhibition reduces renal absorption and lowers the renal threshold for glucose, therefore resulting in increased glucose excretion. Additionally, it contributes to reduced hyperglycaemia and also assists weight loss and blood pressure reduction.
Empagliflozin mechanism of action
Empagliflozin is a sodium glucose co-transporter-2 (SGLT-2) inhibitor. SGLT2 co-transporters are responsible for reabsorption of glucose from the glomerular filtrate in the kidney. The glucuretic effect resulting from SGLT2 inhibition reduces renal absorption and lowers the renal threshold for glucose, resulting in increased glucose excretion. Additionally, it contributes to reduced hyperglycaemia, assists weight loss, and reduces blood pressure.
Dosage forms of Empagliflozin
|Jardiance||10mg||28 Film Coated Tablet||$98.05|
|Jardiance||10mg||90 Film Coated Tablet||$187.95|
|Jardiance||25mg||28 Film Coated Tablet||$108.00|
|Jardiance||25mg||84 Film Coated Tablet||$288.00|
Boehringer Ingelheim Pharmaceuticals, Inc.
Indication of Empagliflozin
Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes.
Toxicity of Empagliflozin
The most commonly reported adverse effects for empaglifozin were urinary tract infections, female genital mycotic infections, and dyslipidemia. Because empagliflozin causes osmotic diuresis adverse reactions related to volume depletion were also reported (decreased systolic blood pressure, dehydration, hypotension, orthostatic hypotension, hypovolemia, and syncope). Impaired renal function and hypoglycemia were also reported.
RX24 Drugs Disclaimer: before buying a Empagliflozin on prescription, consult your healthcare provider. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.
Get lower price on Empagliflozin now!
What is a Jardiance?
Jardiance is an oral hypoglycemic drug. Empagliflozin (active ingredient of the drug Jardiance) is a reversible, highly active, selective and competitive inhibitor of sodium type 2 glucose transporter with the concentration required to inhibit 50% of the enzyme activity (IC50) of 1.3 nmol. The selectivity of empagliflozin is 5,000 times higher than the selectivity of the sodium-dependent glucose transporter of type 1, responsible for the absorption of glucose in the intestine.
In addition, it was found that empagliflozin has a high selectivity for other glucose transporters responsible for glucose homeostasis in various tissues. The sodium type 2 glucose transporter is the main carrier protein responsible for the reabsorption of glucose from the glomeruli back into the bloodstream.
Jardiance improves glycemic control in patients with type 2 diabetes by reducing glucose reabsorption in the kidneys. The amount of glucose excreted by the kidneys through this mechanism depends on the concentration of glucose in the blood and GFR. Inhibition of the sodium type 2 glucose transporter in patients with type 2 diabetes mellitus and hyperglycemia leads to the elimination of glucose by the kidneys.
In clinical studies, it was found that in patients with type 2 diabetes, kidney excretion of glucose increased immediately after the first dose of Jardiance was applied; this effect lasted for 24 hours. The increase in renal glucose excretion persisted until the end of the 4-week treatment period, amounting to an average of 78 g per day with empagliflozin at a dose of 25 mg once a day. In patients with type 2 diabetes, an increase in glucose excretion by the kidneys led to an immediate decrease in plasma glucose concentration.